- Home
- BWLP vs TARS Comparison
BWLP vs TARS Comparison
Compare BWLP & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BWLP | TARS |
|---|---|---|
| Founded | 1935 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.6B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BWLP | TARS |
|---|---|---|
| Price | $24.77 | $68.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $25.05 | ★ $99.80 |
| AVG Volume (30 Days) | 350.2K | ★ 589.3K |
| Earning Date | 11-23-2026 | 11-03-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | N/A | $61.17 |
| Revenue Next Year | N/A | $26.47 |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $11.72 | $53.89 |
| 52 Week High | $26.71 | $91.53 |
Technical Indicators
Market Signals| Indicator | BWLP | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 38.19 |
| Support Level | $23.95 | $60.95 |
| Resistance Level | $25.48 | $69.48 |
| Average True Range (ATR) | 0.79 | 2.94 |
| MACD | -0.17 | -0.71 |
| Stochastic Oscillator | 21.12 | 7.23 |
Price Performance
Historical ComparisonAbout BWLP BW LPG Limited
BW LPG Ltd is an owner and operator of very large gas carriers. It operates in two segments: the Shipping segment, which includes LPG shipping and the Product Services segment, which includes the core shipping business. The Product Services segment derives the majority of the revenue.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.